查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1951254

導管相關血流感染疾病市場 - 全球產業規模、佔有率、趨勢、機會及預測（按治療類型、感染來源、分銷管道、地區和競爭格局分類，2021-2031年）

Catheter Related Bloodstream Infection Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment Type, By Source of Infection, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球導管相關血流感染市場預計將從 2025 年的 16.2 億美元成長到 2031 年的 22.5 億美元，複合年成長率為 5.63%。

該市場涵蓋多種感染預防和治療解決方案，包括抗菌導管、抗生素封管液和固定裝置，旨在降低與血管通路相關的病原體感染風險。推動這一成長的關鍵因素包括需要長期住院治療的慢性病患者人數增加，以及老年人口不斷成長（老年人感染醫院感染的風險更高）。此外，嚴格的監管要求（對可預防感染率高的醫療機構進行處罰）也促使醫療機構採用專業的消毒和導管插入技術。

市場概覽
預測期 2027-2031
市場規模：2025年 16.2億美元
市場規模：2031年 22.5億美元
複合年成長率：2026-2031年 5.63%
成長最快的細分市場 零售藥房
最大的市場 北美洲

然而，與標準導管相比，高階抗菌導管由於高成本，面臨著許多障礙，這限制了其在預算緊張的醫療機構中的應用。此外，嚴格的報銷政策要求醫療機構承擔醫院感染的治療費用，進一步加劇了這種障礙。國際醫院感染控制聯盟（INICC）的報告凸顯了對有效解決方案的持續高臨床需求：2024年，兒童重症監護患者中央靜脈導管相關血流感染的匯總平均發生率為每1000導管日5.37例。

市場促進因素

新型導管封管液和治療方法的引入，為生理食鹽水和肝素沖洗提供了更先進的替代方案，從而對市場產生了決定性的影響，尤其滿足了在不移除感染導管的情況下挽救導管的臨床需求。隨著醫療機構尋求降低中央靜脈導管更換相關併發症風險和操作複雜性，這些創新治療方法正日益受到關注。這些新一代解決方案的有效性正在重塑治療通訊協定。根據Citius Pharmaceuticals於2024年5月發布的公告，一項Minoloc抗菌封管液的III期臨床研究顯示，在導管相關血流感染患者中，整體治療成功率為57.1%，而對照組為37.7%。這些結果支持轉向更高價值的藥物介入措施。

嚴格的感染控制措施是重要的監管力量，迫使醫院投資全面的預防措施和監測技術，以避免受到處罰。監管機構擴大將報銷與安全績效掛鉤，從而推動標準化導管護理通訊協定和先進固定裝置的採用。儘管Leapfrog Group在2024年11月發布的全國數據顯示，自2022年秋季以來，中央靜脈導管相關血流感染的平均分數下降了38%，但合規也帶來了成本壓力。例如，CorMedix新核准的抗菌導管封管液的批發採購價為管瓶249.99美元，這顯示實施這些安全措施需要大量的資金投入。

市場挑戰

全球導管相關血流感染市場面臨一個顯著的障礙，那就是高階抗菌導管的價格遠高於標準靜脈通路裝置。雖然這些先進的解決方案能夠更好地抵禦病原體，但其高昂的價格對預算緊張的醫療機構構成了重大障礙。此外，現行的健保報銷機制也加劇了這一困境：醫院感染的懲罰力道很大，而主動預防性技術卻往往得不到足夠的資金支持。因此，注重成本的採購部門通常會選擇標準導管，這些導管需要嚴格且耗時的消毒通訊協定才能符合監管安全標準，而不是選擇昂貴的抗菌導管。

這種採購行為限制了高利潤抗菌產品的採用，從而直接抑制了市場收入成長。醫療機構如果僅透過流程改善和遵循標準控制措施就能達到所需的安全效果，則可能無需採用昂貴的創新技術。例如，Leapfrog Group 在 2024 年發布的報告顯示，受訪醫院在過去兩年中央靜脈導管相關血流感染率下降了 38%，這反映了這些替代感染控制策略的有效性。這表明，醫療機構目前採用的控制措施能夠有效控制感染率，從而可能減少對高成本導管技術的商業性投資需求。

市場趨勢

隨著感染預防解決方案在醫療保健領域的應用日益廣泛，市場動態也隨之重塑，醫療服務模式正從急性醫院轉向門診和居家照護。這項轉變源自於降低長期住院成本和最大限度減少醫院感染風險的臨床需求，顯著提升了對最佳化靜脈通路裝置和非臨床用戶無菌產品的需求。因此，輸液服務供應商正經歷顯著成長。 2025年10月，Option Care Health在第三季公佈財報上宣布，公司收入淨額達14.35億美元，年增12.2%，主要得益於輸液治療加速居家環境轉移。

同時，人工智慧驅動的數位監測和數據分析正成為變革性力量，使醫療機構能夠自動檢測導管相關病原體。透過將機器學習演算法與電子健康記錄整合，醫療機構可以快速識別感染叢集，簡化報告流程，並顯著減輕感染防治負責人的行政負擔。這項技術整合提高了診斷準確性，並縮短了審核時間。牛津學術出版社2025年11月的一項研究發現，人工智慧輔助的監測審核平均每個病例耗時14分鐘，而專家審查則需要25分鐘，這表明演算法監測顯著提高了效率。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球導管相關血流感染疾病市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依治療類型（抗菌藥物、抗生素封管療法）
    • 依感染源分類（凝固酶陰性葡萄球菌、金黃色葡萄球菌、腸道革蘭氏陰性桿菌、酵母菌、腸球菌和鏈球菌、綠膿桿菌、其他）
    • 按分銷管道（醫院藥房、零售藥房、網路藥房）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美導管相關血流感染疾病市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲導管相關血流感染疾病市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區導管相關血流感染疾病市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲導管相關血流感染疾病市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

10. 南美導管相關血流感染疾病市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

13. 全球導管相關血流感染疾病市場：SWOT 分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Teva Pharmaceutical Industries Ltd.
  • SteriMax Inc.
  • Sanofi SA
  • Pfizer Inc.
  • Novartis AG
  • Merck & Co., Inc.
  • GSK plc
  • Fresenius SE & Co. KGaA
  • Eli Lilly and Company
  • Aurobindo Pharma Limited

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 27656

The Global Catheter Related Bloodstream Infection Market is projected to expand from USD 1.62 Billion in 2025 to USD 2.25 Billion by 2031, reflecting a compound annual growth rate of 5.63%. This market encompasses a range of infection prevention and treatment solutions, including antimicrobial catheters, antibiotic locks, and site securement devices, all designed to mitigate pathogen risks associated with vascular access. The primary forces driving this growth include the increasing prevalence of chronic diseases necessitating prolonged hospitalization and a growing geriatric population vulnerable to hospital-acquired conditions. Additionally, strict regulatory mandates that penalize healthcare facilities for preventable infection rates are compelling the adoption of specialized sterilization and catheter technologies.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 1.62 Billion
Market Size 2031USD 2.25 Billion
CAGR 2026-20315.63%
Fastest Growing SegmentRetail Pharmacies
Largest MarketNorth America

However, the market encounters significant obstacles due to the high cost of premium antimicrobial catheters compared to standard options, which restricts their adoption in budget-constrained healthcare settings. This barrier is exacerbated by rigorous reimbursement policies that hold medical facilities financially responsible for treating hospital-acquired infections. Underscoring the continued clinical necessity for effective solutions, the International Nosocomial Infection Control Consortium reported in 2024 that the pooled mean central line-associated bloodstream infection rate among pediatric intensive care patients was 5.37 episodes per 1,000 catheter days.

Market Driver

The introduction of novel catheter lock solutions and therapies is critically influencing the market by offering advanced alternatives to traditional saline or heparin flushes, specifically addressing the clinical need to salvage infected devices rather than removing them. These innovative therapies are gaining traction as healthcare providers seek to reduce the morbidity and logistical complexity associated with central venous catheter replacement. The efficacy of these next-generation solutions is reshaping treatment protocols; according to Citius Pharmaceuticals in May 2024, the Phase 3 Trial of Mino-Lok Antibiotic Lock Solution demonstrated an overall treatment success rate of 57.1% in patients with catheter-related bloodstream infections compared to 37.7% in the control arm, validating the shift toward high-value pharmacological interventions.

The implementation of stringent infection control mandates serves as a primary regulatory force, pushing hospitals to invest in comprehensive prevention bundles and surveillance technologies to avoid financial penalties. Regulatory bodies are increasingly linking reimbursement to safety performance, driving the adoption of standardized catheter care protocols and advanced securement devices. While recent national data from The Leapfrog Group in November 2024 indicates that average central line-associated bloodstream infection scores decreased by 38% since the fall of 2022, compliance brings cost pressures; for instance, CorMedix Inc. established a wholesale acquisition cost of $249.99 per vial for its newly approved antimicrobial catheter lock solution in 2024, illustrating the significant financial investment required to integrate these safeguards.

Market Challenge

The Global Catheter Related Bloodstream Infection Market faces a distinct obstacle regarding the prohibitive cost of premium antimicrobial catheters compared to standard vascular access devices. While these advanced solutions offer enhanced pathogen protection, their elevated price creates a significant barrier for healthcare facilities managing restricted budgets, a friction intensified by reimbursement structures that impose strict penalties for hospital-acquired conditions but often fail to provide adequate funding for upfront preventative technologies. Consequently, cost-sensitive procurement departments frequently opt for standard catheters, substituting expensive device-based solutions with rigorous, labor-intensive sterility protocols to meet regulatory safety standards.

This purchasing behavior directly restricts market revenue growth by limiting the adoption volume of high-margin antimicrobial products. Medical facilities may bypass expensive innovations if they can achieve required safety outcomes through process improvements and standard bundle compliance alone. Highlighting the effectiveness of these alternative containment strategies, The Leapfrog Group noted in 2024 that central line-associated bloodstream infections decreased by 38% over the last two years across surveyed hospitals, suggesting that facilities are effectively controlling infection rates through current measures, potentially diminishing the perceived commercial necessity for investing in higher-cost catheter technologies.

Market Trends

The expansion of infection prevention solutions into home healthcare settings is reshaping market dynamics as care delivery shifts from acute hospital environments to ambulatory and domiciliary models. This transition is driven by the clinical necessity to reduce long-term hospitalization costs and minimize nosocomial exposure, fostering high demand for vascular access devices and sterility products optimized for non-clinical users. Consequently, infusion service providers are witnessing substantial growth; according to Option Care Health in October 2025, the company reported net revenue of $1.435 billion in its third-quarter earnings call, representing a 12.2% increase over the prior year due to the accelerated migration of infusion therapies to the home setting.

Simultaneously, the utilization of AI-driven digital surveillance and data analytics is emerging as a transformative force, enabling healthcare facilities to automate the complex detection of catheter-related pathogens. By integrating machine learning algorithms with electronic health records, institutions can rapidly identify infection clusters and streamline reporting compliance, significantly reducing the administrative burden on infection preventionists. This technological integration enhances diagnostic accuracy and cuts review time; according to Oxford Academic in November 2025, AI-assisted surveillance review required a median of 14 minutes per case compared to 25 minutes for expert review, demonstrating significant efficiency gains through algorithmic monitoring.

Key Market Players

  • Teva Pharmaceutical Industries Ltd.
  • SteriMax Inc.
  • Sanofi S.A.
  • Pfizer Inc.
  • Novartis AG
  • Merck & Co., Inc.
  • GSK plc
  • Fresenius SE & Co. KGaA
  • Eli Lilly and Company
  • Aurobindo Pharma Limited

Report Scope

In this report, the Global Catheter Related Bloodstream Infection Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Catheter Related Bloodstream Infection Market, By Treatment Type

  • Anti-microbial Agents
  • Antibiotic Lock Therapy

Catheter Related Bloodstream Infection Market, By Source of Infection

  • Coagulase-negative Staphylococcus
  • S. Aureus
  • Enteric Gram-negative Bacilli
  • Yeasts
  • Enterococci & Streptococci
  • Pseudomonas
  • Others

Catheter Related Bloodstream Infection Market, By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Catheter Related Bloodstream Infection Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Catheter Related Bloodstream Infection Market.

Available Customizations:

Global Catheter Related Bloodstream Infection Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Catheter Related Bloodstream Infection Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment Type (Anti-microbial Agents, Antibiotic Lock Therapy)
    • 5.2.2. By Source of Infection (Coagulase-negative Staphylococcus, S. Aureus, Enteric Gram-negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas, Others)
    • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Catheter Related Bloodstream Infection Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment Type
    • 6.2.2. By Source of Infection
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Catheter Related Bloodstream Infection Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Treatment Type
        • 6.3.1.2.2. By Source of Infection
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Canada Catheter Related Bloodstream Infection Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Treatment Type
        • 6.3.2.2.2. By Source of Infection
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Mexico Catheter Related Bloodstream Infection Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Treatment Type
        • 6.3.3.2.2. By Source of Infection
        • 6.3.3.2.3. By Distribution Channel

7. Europe Catheter Related Bloodstream Infection Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment Type
    • 7.2.2. By Source of Infection
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Catheter Related Bloodstream Infection Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Treatment Type
        • 7.3.1.2.2. By Source of Infection
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. France Catheter Related Bloodstream Infection Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Treatment Type
        • 7.3.2.2.2. By Source of Infection
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. United Kingdom Catheter Related Bloodstream Infection Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Treatment Type
        • 7.3.3.2.2. By Source of Infection
        • 7.3.3.2.3. By Distribution Channel
    • 7.3.4. Italy Catheter Related Bloodstream Infection Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Treatment Type
        • 7.3.4.2.2. By Source of Infection
        • 7.3.4.2.3. By Distribution Channel
    • 7.3.5. Spain Catheter Related Bloodstream Infection Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Treatment Type
        • 7.3.5.2.2. By Source of Infection
        • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Catheter Related Bloodstream Infection Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment Type
    • 8.2.2. By Source of Infection
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Catheter Related Bloodstream Infection Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Treatment Type
        • 8.3.1.2.2. By Source of Infection
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. India Catheter Related Bloodstream Infection Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Treatment Type
        • 8.3.2.2.2. By Source of Infection
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Japan Catheter Related Bloodstream Infection Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Treatment Type
        • 8.3.3.2.2. By Source of Infection
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. South Korea Catheter Related Bloodstream Infection Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Treatment Type
        • 8.3.4.2.2. By Source of Infection
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Australia Catheter Related Bloodstream Infection Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Treatment Type
        • 8.3.5.2.2. By Source of Infection
        • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Catheter Related Bloodstream Infection Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment Type
    • 9.2.2. By Source of Infection
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Catheter Related Bloodstream Infection Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Treatment Type
        • 9.3.1.2.2. By Source of Infection
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. UAE Catheter Related Bloodstream Infection Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Treatment Type
        • 9.3.2.2.2. By Source of Infection
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. South Africa Catheter Related Bloodstream Infection Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Treatment Type
        • 9.3.3.2.2. By Source of Infection
        • 9.3.3.2.3. By Distribution Channel

10. South America Catheter Related Bloodstream Infection Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Treatment Type
    • 10.2.2. By Source of Infection
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Catheter Related Bloodstream Infection Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Treatment Type
        • 10.3.1.2.2. By Source of Infection
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Colombia Catheter Related Bloodstream Infection Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Treatment Type
        • 10.3.2.2.2. By Source of Infection
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. Argentina Catheter Related Bloodstream Infection Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Treatment Type
        • 10.3.3.2.2. By Source of Infection
        • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Catheter Related Bloodstream Infection Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Teva Pharmaceutical Industries Ltd.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. SteriMax Inc.
  • 15.3. Sanofi S.A.
  • 15.4. Pfizer Inc.
  • 15.5. Novartis AG
  • 15.6. Merck & Co., Inc.
  • 15.7. GSK plc
  • 15.8. Fresenius SE & Co. KGaA
  • 15.9. Eli Lilly and Company
  • 15.10. Aurobindo Pharma Limited

16. Strategic Recommendations

17. About Us & Disclaimer